Fig. 4: In vivo CAR T cell experimental murine model of xenograft IL-1RAP CAR+ HL-60 AML cell line. | Cancer Gene Therapy

Fig. 4: In vivo CAR T cell experimental murine model of xenograft IL-1RAP CAR+ HL-60 AML cell line.

From: Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch

Fig. 4

Immunodeficient NSG-S mice were irradiated (2.5 Gy) 1 day before injection of 106 luciferase HL-60 or luciferase IL-1RAP CAR+ HL-60 cells. a After AML tumor engraftment, mice were left untreated (UT), treated with AP1903 (50 μg i.p.), treated with control T cells (mock), or treated with IL-1RAP CAR T cells (107 cells). From day 2 after tumor infusion, mice were monitored for tumor progression until day 40 by bioluminescence imaging (BLI). (×) dead mice. (▶) the time of injection of untransduced T cells or CAR T cells. Radiance scale is provided for D0 to D16 and for D16 to D40. b Radiance curves of the in vivo bioluminescent signal (radiance p/s/cm2/sr) recorded using BLI from the time of injection of IL-1RAP CAR T cells at D0 to D40. AP1903 (blue line), CAR T cells (red line). ***p < 0.01.

Back to article page